Benjamin R Huebner1, Ernest E Moore2, Hunter B Moore3, Raymond Shepherd-Singh4, Angela Sauaia2, Gregory R Stettler3, Geoffrey R Nunns3, Christopher C Silliman5. 1. Department of Surgery, University of Colorado, Aurora, Colorado. Electronic address: benjamin.huebner@ucdenver.edu. 2. Department of Surgery, University of Colorado, Aurora, Colorado; Department of Surgery, Denver Health Medical Center, Denver, Colorado. 3. Department of Surgery, University of Colorado, Aurora, Colorado. 4. Department of Surgery, Denver Health Medical Center, Denver, Colorado. 5. Department of Pediatrics, University of Colorado, Aurora, Colorado; Bonfils Blood Center, Denver, Colorado.
Abstract
BACKGROUND: Plasma-first resuscitation attenuates trauma-induced coagulopathy (TIC); however, the logistics of plasma-first resuscitation require thawed plasma (TP) be readily available due to the obligatory thawing time of fresh frozen plasma (FFP). The current standard is storage of TP for up to 5 days at 4°C, based on factor levels at outdate, for use in patients at risk for TIC, but there remains a 2.2% outdated wastage rate. However, the multitude of plasma proteins in attenuating TIC remains unknown. We hypothesize that TP retains the ability to enhance clotting and reduce tPA-induced fibrinolysis at 14-day storage. METHODS: FFP was thawed and stored at 4°C at the following intervals: 14, 10, 7, 5, 3, and 1-day prior to the experiment. Healthy volunteers underwent blood draws followed by 50% dilution with TP stored at previously mentioned intervals as well as FFP, normal saline (NS), albumin, and whole blood (WB) control. Samples underwent tPA-modified (75 ng/mL) thrombelastography (TEG) with analysis of R-time, angle, maximum amplitude (MA), and LY30. RESULTS: TEG properties did not change significantly over the thawed storage. 14-day TP retained the ability to inhibit tPA-induced hyperfibrinolysis (median LY30% 9.6%) similar to FFP (5.6%), WB (14.6%), and superior to albumin (59.3%) and NS (58.1%). 14-day TP also retained faster clot formation (median angle, 66.2°) and superior clot strength (MA, 61.5 mm) to albumin (34.8°, 21.6 mm) and NS (41.6°, 32.2 mm). CONCLUSIONS: TP plasma stored for 14 days retains clot-enhancing ability and resistance to clot degradation similar to FFP. A clinical trial is needed to validate these in vitro results.
BACKGROUND: Plasma-first resuscitation attenuates trauma-induced coagulopathy (TIC); however, the logistics of plasma-first resuscitation require thawed plasma (TP) be readily available due to the obligatory thawing time of fresh frozen plasma (FFP). The current standard is storage of TP for up to 5 days at 4°C, based on factor levels at outdate, for use in patients at risk for TIC, but there remains a 2.2% outdated wastage rate. However, the multitude of plasma proteins in attenuating TIC remains unknown. We hypothesize that TP retains the ability to enhance clotting and reduce tPA-induced fibrinolysis at 14-day storage. METHODS: FFP was thawed and stored at 4°C at the following intervals: 14, 10, 7, 5, 3, and 1-day prior to the experiment. Healthy volunteers underwent blood draws followed by 50% dilution with TP stored at previously mentioned intervals as well as FFP, normal saline (NS), albumin, and whole blood (WB) control. Samples underwent tPA-modified (75 ng/mL) thrombelastography (TEG) with analysis of R-time, angle, maximum amplitude (MA), and LY30. RESULTS: TEG properties did not change significantly over the thawed storage. 14-day TP retained the ability to inhibit tPA-induced hyperfibrinolysis (median LY30% 9.6%) similar to FFP (5.6%), WB (14.6%), and superior to albumin (59.3%) and NS (58.1%). 14-day TP also retained faster clot formation (median angle, 66.2°) and superior clot strength (MA, 61.5 mm) to albumin (34.8°, 21.6 mm) and NS (41.6°, 32.2 mm). CONCLUSIONS:TP plasma stored for 14 days retains clot-enhancing ability and resistance to clot degradation similar to FFP. A clinical trial is needed to validate these in vitro results.
Authors: Deborah J Novak; Yu Bai; Rhonda K Cooke; Marisa B Marques; Magali J Fontaine; Jerome L Gottschall; Patricia M Carey; Richard M Scanlan; Eberhard W Fiebig; Ira A Shulman; Janice M Nelson; Sherri Flax; Veda Duncan; Jennifer A Daniel-Johnson; Jeannie L Callum; John B Holcomb; Erin E Fox; Sarah Baraniuk; Barbara C Tilley; Martin A Schreiber; Kenji Inaba; Sandro Rizoli; Jeanette M Podbielski; Bryan A Cotton; John R Hess Journal: Transfusion Date: 2015-03-30 Impact factor: 3.157
Authors: Nena Matijevic; Vadim Kostousov; Yao-Wei W Wang; Charles E Wade; Weiwei Wang; Phillip Letourneau; Elizabeth Hartwell; Rosemary Kozar; Tien Ko; John B Holcomb Journal: J Trauma Date: 2011-01
Authors: Zayde A Radwan; Yu Bai; Nena Matijevic; Deborah J del Junco; James J McCarthy; Charles E Wade; John B Holcomb; Bryan A Cotton Journal: JAMA Surg Date: 2013-02 Impact factor: 14.766
Authors: Bryan A Cotton; John A Harvin; Vadim Kostousouv; Kristin M Minei; Zayde A Radwan; Herbert Schöchl; Charles E Wade; John B Holcomb; Nena Matijevic Journal: J Trauma Acute Care Surg Date: 2012-08 Impact factor: 3.313
Authors: Matthew A Borgman; Philip C Spinella; Jeremy G Perkins; Kurt W Grathwohl; Thomas Repine; Alec C Beekley; James Sebesta; Donald Jenkins; Charles E Wade; John B Holcomb Journal: J Trauma Date: 2007-10
Authors: Michael P Chapman; Ernest E Moore; Hunter B Moore; Eduardo Gonzalez; Fabia Gamboni; James G Chandler; Sanchayita Mitra; Arsen Ghasabyan; Theresa L Chin; Angela Sauaia; Anirban Banerjee; Christopher C Silliman Journal: J Trauma Acute Care Surg Date: 2016-01 Impact factor: 3.313
Authors: Gregory R Stettler; Ernest E Moore; Geoffrey R Nunns; Marguerite Kelher; Anirban Banerjee; Christopher C Silliman Journal: J Surg Res Date: 2020-12-02 Impact factor: 2.192
Authors: Gregory R Stettler; Ernest E Moore; Benjamin R Huebner; Geoffrey R Nunns; Hunter B Moore; Julia R Coleman; Marguerite Kelher; Anirban Banerjee; Christopher C Silliman Journal: Vox Sang Date: 2020-09-07 Impact factor: 2.144